M
Matthew D. Hill Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
High Impact
CEO
faculty
33 h-index
181 pubs
9,381 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Matthew D. Hill's research group investigates molecular mechanisms underlying disease and the development of novel therapeutic agents. His work has focused on the development of BET inhibitors for cancer treatment, exploring different chemotypes and optimizing pharmacokinetic properties. Additionally, his research has included the study of SAGE-718, a modulator targeting N-methyl-D-aspartate receptors for potential treatment of cognitive impairment.
Hill holds a high-impact researcher designation, evidenced by an h-index of 33 and over 9,000 citations across 182 publications. He leads a research group and maintains an active lab website, indicating ongoing research activities. His recent publications also extend to financial topics, including liquidity management and corporate cash holdings, suggesting a broader range of scholarly interests or collaborative projects.
Collaborations within Arkansas State University are documented, including shared publications with Katie Hill and another researcher named Matthew Hill.
Metrics
- h-index: 33
- Publications: 181
- Citations: 9,381
Selected Publications
-
Liquidity Management and Gender: Evidence from U.S. Households (2025)
-
The Persistent Rise in Corporate Cash Holdings (2025)
-
An Investigation of Trades That Move the BBO Using Strings (2025)
Collaboration Network
Top Collaborators
Haiquan Fang
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
John S. Tokarski
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Zuzana Haarhoff
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Melissa Kramer
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
J. S. Morrison
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Richard A. Westhouse
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
S. Sheriff
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Chunhong Yan
Bristol-Myers Squibb (United States) (US)
3 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Carolynn Fanslau
Bristol-Myers Squibb (United States) (US)
2 shared publications
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Christine Huang
Bristol-Myers Squibb (United States) (US)
2 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Krista Menard
Bristol-Myers Squibb (United States) (US)
2 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Laura Monereau
Bristol-Myers Squibb (United States) (US)
2 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Eric Shields
Bristol-Myers Squibb (United States) (US)
2 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Ching Kim Tye
Bristol-Myers Squibb (United States) (US)
2 shared publications
- Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Gerry Everlof
Bristol-Myers Squibb (United States) (US)
2 shared publications
- Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype
- Development of BET inhibitors as potential treatments for cancer: A search for structural diversity
Similar Researchers
Based on overlapping research topics
Baku Acharya
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Receptor Mechanisms and Signaling
Fang Liu
National Center for Toxicological Research
Cancer Treatment and Pharmacology
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Kayla Hefner
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Receptor Mechanisms and Signaling
Jiřı́ Novotný
University of Arkansas at Fayetteville
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Receptor Mechanisms and Signaling
Han M
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Scott A. Stuart
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders